Paul Hartmann (DB:PHH2) Stock Cheapens As Margin Debate Persists

Paul Hartmann stock came into this earnings season looking cheap on a P/E of 7.1x with a 4% dividend, yet shares have slipped over the past month and were down again around the results. The market is treating this as a value story that might never re rate. The headline from H1 says something different.

Earnings per share for the half year landed at €15.35 on revenue of €1,251.95m. That supports trailing earnings of €28.13 per share and a trailing net margin of 4%. For a medical equipment group on this kind of multiple, profitability is the key debate.

Love the low P/E and dividend support at Paul Hartmann but concerned that a 4% net margin leaves limited room for error in the medical equipment space? Take a look at our hand picked list of resilient compounders in the list of solid balance sheet and fundamentals stocks (434 results).

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): €1,251.95m vs. €1,214.00m (higher period on period)
• Net Income (H1 2026 vs. H1 2025): €54.53m vs. €15.85m (very strong increase)
• Basic EPS (H1 2026 vs. H1 2025): €15.35 vs. €4.46 (very strong increase)
• Trailing Net Margin (TTM to H1 2026 vs. prior year): 4.0% vs. 3.3% (improved profitability on a trailing basis)

Prefer clean visual charts instead of scrolling through pages of earnings figures and ratios for Paul Hartmann? See the company’s full financial picture with a focus on its valuation in our company report for Paul Hartmann.

Paul Hartmann earnings back a cautious bullish view

The latest half year from Paul Hartmann gives some support to the defensive healthcare story. Revenue of €1,251.95m is higher than the prior period and net income has moved up to €54.53m, which lifts trailing earnings per share to €28.13. A trailing net margin of 4% is above the prior 3.3%. For a consumables focused medical equipment group that relies on recurring demand, this combination of steady top line progress and firmer margins points to a business model that is holding up operationally.

Margin sensitivity still matters for Paul Hartmann

The bearish narrative around thin margins and procurement pressure is not swept away by one strong half. Even at 4%, Paul Hartmann still runs on a relatively slim net margin for a medical equipment group, which leaves less room to absorb cost shocks or pricing pushback. Recent share price performance, with the stock down over the past 7, 30 and 90 days, suggests investors remain cautious. The direction of profitability has improved, yet the financial profile still fits a margin sensitive supplier that needs continued discipline on costs and contracts.

With earnings growing faster than the five year trend and a trailing P/E of 7.1x against a much higher implied cash flow value, the real question is whether Paul Hartmann has the balance sheet strength and cash generation to support this profile without surprise strain on liquidity or debt. Check the full solvency, liquidity and cash runway breakdown in our financial health analysis of Paul Hartmann stock.

Stay Ahead Of Your Next Move

If the combination of a low P/E, 4% dividend and slim margins at Paul Hartmann has caught your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for a setup that fits your plan. Once you are invested, keep your focus on what really matters by using the Portfolio Command Center to cut through market noise and surface the key events that could affect your holdings. For a longer term view, plug into crowd insights and different angles on Paul Hartmann and its peers through the Community. This way you can spot potential catalysts or emerging risks early and stay a step ahead of the wider market.

Seeking Alternatives Beyond Paul Hartmann?

Fresh ideas often move first. While attention clusters around Paul Hartmann, other stocks may be building breakout momentum under the radar for now. Do not get caught dropping back; consider your options carefully.

• Target resilient cash generators that can weather shocks while still compounding. You can start with a curated 282 resilient stocks with low risk scores before the crowd fully catches on.
• Look for potential upside in overlooked growth stories by scanning a focused set of 610 high quality undiscovered gems that could be building momentum while attention stays elsewhere.
• Identify potential income-focused candidates with staying power by reviewing high-yield opportunities in the 449 dividend fortresses while yields remain elevated and competition is still light.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com